ORIC Oric Pharmaceuticals, Inc.

CIK 0001796280 19 ready 8-Ks latest May 4, 2026, 7:59 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 19

Latest filing May 4, 2026, 7:59 PM ET

Top materiality 0.85

Event mix other_material ×10 · earnings ×7 · other ×2

Sentiment 7 pos · 1 neg · 11 neu

Latest earnings reported 2026-Q1

Recent 8-K filings for ORIC

Highest-materiality recent filing

ORIC raises $125M; ORIC-944 Phase 1b shows 59% PSA50 response in mCRPC

May 28, 2025, 7:59 PM ET other material materiality 0.85 positive item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

$125M private placement of 19.2M shares/pre-funded warrants at $6.50/share; led by SR One; close expected May 29, 2025.
Pro forma cash into 2H 2027 funds through first ORIC-944 Phase 3 registrational trial primary endpoint.

Read filing →

May 4, 2026, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

ORIC Q1 2026: rinzimetostat RP3D for Phase 3; $419.7M cash; enozertinib data due 2H 2026

Rinzimetostat 400 mg QD + darolutamide data showed landmark rPFS 93%/84%/84% at 3/4/5 months; no Grade 4/5 TRAEs.
February 23, 2026, 6:59 PM ET earnings materiality 0.60 positive item 2.02 item 9.01

ORIC reports Q4 2025 cash of $392.3M; positive Phase 1b data for rinzimetostat and enozertinib

Cash and investments $392.3M at Dec 31, 2025; proforma $412.3M after $20M ATM in 2026; runway into 2H 2028.
November 13, 2025, 6:59 PM ET other material materiality 0.75 positive item 2.02 item 9.01

ORIC Pharma Q3 2025: $413M cash; ORIC-944 dose exploration complete with positive data

Cash and investments of $413M as of Sep 30, 2025; expected to fund operating plan into 2H 2028.
August 12, 2025, 7:59 PM ET other material materiality 0.75 negative item 2.02 item 9.01 item 2.05 ◈ Restructurings & Charges

ORIC Pharma restructures, cuts 20% workforce, and extends cash runway to 2H 2028

Initiated strategic pipeline prioritization, eliminating discovery research and reducing workforce by ~20%; expects ~$1.9M one-time charge in Q3 2025.
May 28, 2025, 7:59 PM ET other material materiality 0.85 positive item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

ORIC raises $125M; ORIC-944 Phase 1b shows 59% PSA50 response in mCRPC

$125M private placement of 19.2M shares/pre-funded warrants at $6.50/share; led by SR One; close expected May 29, 2025.
May 5, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

ORIC Q1 cash $224M; extends runway to 2027; plans Phase 3 for 2 programs in 2026

Cash and investments $223.8M at March 31, 2025; expected to fund operations into 2027 (vs previous guidance of late 2026).
February 25, 2025, 6:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

ORIC updates registrational plans for lead drugs, extends cash runway into 2027

ORIC-944 first Phase 3 trial in mCRPC expected 1H 2026; combination dose escalation data in 1H and 2H 2025.
February 18, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

ORIC Pharma Q4/FY2024: $256M cash; R&D spend $114.1M; seven data readouts anticipated

Cash $256M as of Dec 31, 2024; expected to fund operations into late 2026.
August 12, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

ORIC Pharma Q2 cash $308.5M; ORIC-114 expansion and ORIC-944 combo dosing underway

Cash and investments $308.5M as of June 30, 2024; expected to fund operations into late 2026.
May 6, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases

ORIC Pharma reports Q1 2024 cash of $331.5M; advances ORIC-114 and ORIC-944 trials

Cash and investments $331.5M as of March 31, 2024, expected to fund operations into late 2026.

Earnings & guidance

2026-Q1 EPS reported -$0.34 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

7 positive 1 negative 11 neutral

source · ORIC on sec.gov